InnoCan Pharma Faces Crisis: $7.23 Stock, Negative P/E, OTC Challenges
InnoCan Pharma’s sharp decline to $7.23 and negative P/E reveals urgent strategic and financial challenges—can the biotech firm regain investor confidence and turn the tide?
2 minutes to read